Pfizer’s Herceptin biosimilar succeeds in key breast cancer
Pfizer Inc said its experimental biosimilar of Roche Holding AG’s blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study. Biotech drugs such as Herceptin are made in living cells, and then extracted and purified. They are more complex than traditional drugs and cannot be copied with precision. Unlike generic drugs, which are interchangeable with their branded counterparts, biosimilars approved by the U.S. Food and Drug Administration to date ...